Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00211
|
|||||
| Drug Name |
Apixaban
|
|||||
| Synonyms |
1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd; Apixaban (JAN/USAN/INN); BMS 562247-01; BMS-562247; BMS-562247-01; BMS-562247-01, Apixaban; Eliquis (TN); GG2; Ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Thrombosis [ICD11: BD71.4, BD72] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C25H25N5O4
|
|||||
| Canonical SMILES |
COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
|
|||||
| InChI |
InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
|
|||||
| InChIKey |
QNZCBYKSOIHPEH-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 503612-47-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 459.5 | Topological Polar Surface Area | 111 | ||
| Heavy Atom Count | 34 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
2.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103535612
, 104253239
, 109693404
, 124757362
, 124772059
, 125164166
, 125433570
, 126644898
, 126665798
, 134339057
, 135252374
, 135727449
, 135727826
, 136367462
, 136368094
, 136920385
, 137183704
, 139455355
, 144115617
, 15178464
, 152258806
, 152343992
, 152344098
, 160647657
, 160874191
, 160962913
, 160968889
, 162011738
, 163884621
, 164194092
, 164777207
, 165247616
, 170497908
, 172912849
, 17397366
, 174006823
, 174549337
, 175266926
, 175427077
, 178103006
, 22578033
, 26736936
, 40272539
, 46519072
, 51992439
, 53812906
, 56310620
, 57374335
, 99375349
, 99444299
|
|||||
| ChEBI ID |
CHEBI:72296
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Apixaban was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013 Apr;41(4):827-35. | |||||
| 3 | Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016 Apr;16(2):119-27. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.